摘要
目的分析替格瑞洛应用于冠心病(CHD)患者经皮冠状动脉介入术(PCI)治疗中的效果及对凝血功能的影响。方法选取2020年1月至2023年12月山东大学第三人民医院行PCI的90例CHD患者,按照随机数字表法分为对照组(给予氢氯吡格雷,45例)和观察组(给予替格瑞洛,45例)。比较两组凝血功能[活化部分凝血活酶时间(APTT)、凝血酶原时间(PT)、凝血酶时间(TT)]、血小板参数[血小板反应指数(PRI)、血小板最大聚集率(MPAR)]、氧化应激指标[超氧化物歧化酶(SOD)、丙二醛(MDA)]。结果观察组治疗后的APTT、PT、TT长于对照组,PRI、MPAR、MDA低于对照组,SOD高于对照组,差异有统计学意义(P<0.05)。结论在CHD患者行PCI期间给予替格瑞洛,可以抑制血小板聚集,改善凝血功能,缓解氧化应激损伤。
Objective To analyze the effect of Ticagrelor on percutaneous coronary intervention(PCI)in patients with coronary heart disease(CHD)and its effect on coagulation function.Methods A total of 90 patients with CHD who underwent PCI in Jinan Third People's Hospital from January 2020 to December 2023 were selected as research objects.According to the random number table method,they were divided into control group(given Hydroclopidogrel,45 cases)and observation group(given Ticagrelor,45 cases).The coagulation function(activated partial thromboplastin time[APTT],prothrombin time[PT],thrombin time[TT]),platelet parameters(platelet response index[PRI],maximum platelet aggregation rate[MPAR])and oxidative stress index(superoxide dismutase[SOD],malondialdehyde[MDA])of the two groups were compared.Results After treatment,APTT,PT and TT in observation group were longer than those in control group,PRI,MPAR and MDA were lower than those in control group,and SOD was higher than that in control group,the differences were statistically significant(P<0.05).Conclusion Ticagrelor administration during PCI in CHD patients can inhibit platelet aggregation,improve coagulation function,and alleviate oxidative stress damage.
作者
姜春影
王玉霞
JIANG Chunying;WANG Yuxia(Department of Pharmacy,Jinan Third People's Hospital,Shandong Province,Jinan 250132,China)
出处
《中国当代医药》
2025年第3期39-42,共4页
China Modern Medicine
关键词
冠心病
介入治疗
替格瑞洛
凝血功能
Coronary heart disease
Interventional therapy
Ticagrelor
Coagulation function
